Literature DB >> 30946815

Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma.

Beili Wang1, Jie Zhu1, Xiaolu Ma1, Hao Wang1, Shuangjian Qiu2, Baishen Pan1, Jian Zhou2, Jia Fan2, Xinrong Yang2, Wei Guo3, Yunfeng Cheng4.   

Abstract

BACKGROUND: The venous thromboembolism, which may be caused by increased platelet activation, is a risk factor for tumor prognosis. We determined the platelet activation status for diagnosis and predicting postoperative prognosis of hepatocellular carcinoma.
METHODS: We conducted a prospective study of 191 patients diagnosed with HCC at Zhongshan Hospital from April 2016 to July 2016 as well as 99 healthy people. The platelet activation status was assessed by 2 platelet markers, PAC-1 and CD62p, using flow cytometry. The patients were treated with TACE or resection and monitored for ≥6 months. The diagnostic value of marker-positive platelets was determined by the receiver operating characteristic curve and the postoperative value were analyzed using the Kaplan-Meier method and COX regression model.
RESULTS: All the 3 groups with high levels of marker-positive platelets were likely to be diagnosed with HCC and the PAC-1+ percentage had the best efficacy. The univariate analysis showed that the levels of PAC-1+ and CD62p+ platelets was risker factors for poor postoperative prognosis after both TACE and resection. Moreover, the multivariate analysis revealed that the level of PAC-1+ platelets was an independent risk factor for poor prognosis.
CONCLUSIONS: The PAC-1+ percentage of platelets is a new indicator for diagnosis and predicting postoperative prognosis.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  PAC-1; Platelet activation; Postoperative prognosis; Radical resection; TACE

Mesh:

Substances:

Year:  2019        PMID: 30946815     DOI: 10.1016/j.cca.2019.03.1634

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  ICAM-1 Activates Platelets and Promotes Endothelial Permeability through VE-Cadherin after Insufficient Radiofrequency Ablation.

Authors:  Jian Kong; Changyu Yao; Shuying Dong; Shilun Wu; Yangkai Xu; Ke Li; Liang Ji; Qiang Shen; Qi Zhang; Rui Zhan; Hongtu Cui; Changping Zhou; Haigang Niu; Guoming Li; Wenbing Sun; Lemin Zheng
Journal:  Adv Sci (Weinh)       Date:  2021-01-04       Impact factor: 16.806

2.  Metformin Mitigated Obesity-Driven Cancer Aggressiveness in Tumor-Bearing Mice.

Authors:  Chun-Jung Chen; Chih-Cheng Wu; Cheng-Yi Chang; Jian-Ri Li; Yen-Chuan Ou; Wen-Ying Chen; Su-Lan Liao; Jiaan-Der Wang
Journal:  Int J Mol Sci       Date:  2022-08-15       Impact factor: 6.208

Review 3.  Platelets: The Emerging Clinical Diagnostics and Therapy Selection of Cancer Liquid Biopsies.

Authors:  Yiming Meng; Jing Sun; Yang Zheng; Guirong Zhang; Tao Yu; Haozhe Piao
Journal:  Onco Targets Ther       Date:  2021-05-25       Impact factor: 4.147

4.  CD62P (P-selectin) expression as a platelet activation marker in patients with liver cirrhosis with and without cholestasis.

Authors:  Sara Hegazy; Maha Elsabaawy; Mohamed Eltabakh; Reham Hammad; Hanan Bedair
Journal:  Clin Exp Hepatol       Date:  2021-06-30

Review 5.  Till Death Do Us Part-The Multifaceted Role of Platelets in Liver Diseases.

Authors:  Marion Mussbacher; Laura Brunnthaler; Anja Panhuber; Patrick Starlinger; Alice Assinger
Journal:  Int J Mol Sci       Date:  2021-03-18       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.